Amryt Pharma plc (AMYT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for AMYT in the last 30 days. The most recent was published Apr 24, 2023.
Latest news
25 items- SECSEC Form EFFECT filed by Amryt Pharma plcEFFECT - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form 15F-12B filed by Amryt Pharma plc15F-12B - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form EFFECT filed by Amryt Pharma plcEFFECT - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form EFFECT filed by Amryt Pharma plcEFFECT - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form POS AM filed by Amryt Pharma plcPOS AM - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form POS AM filed by Amryt Pharma plcPOS AM - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form POS AM filed by Amryt Pharma plcPOS AM - Amryt Pharma plc (0001783010) (Filer)
- 13D/GSEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
- SECSEC Form 6-K filed by Amryt Pharma plc6-K - Amryt Pharma plc (0001783010) (Filer)
- SECSEC Form 25-NSE filed by Amryt Pharma plc25-NSE - Amryt Pharma plc (0001783010) (Subject)
- PRChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc● Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra
- PRChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma PlcChiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp
- SECSEC Form 6-K filed by Amryt Pharma plc6-K - Amryt Pharma plc (0001783010) (Filer)
- PRHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementHigh Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa
- SECSEC Form 6-K filed by Amryt Pharma plc6-K - Amryt Pharma plc (0001783010) (Filer)
- NEWSAmryt Pharma Shareholders Approve Acquisition Of Amryt Pharma By Chiesi Farmaceutici; Terms Not Disclosed
- PRAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today's shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi Farmaceutici S.p.A., (the "Transaction") were duly passed. The full text of each resolution was included in the notice of the shareholder meetings posted to shareholders on Febr
- NEWSTop 5 Health Care Stocks That Are Ticking Portfolio BombsThe most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Immuneering Corporation (NASDAQ:IMRX) Immuneering posted a narrower-than-expected quarterly loss. “2022 was a year of important progress towards our goal of creating impactful
- SECSEC Form 6-K filed by Amryt Pharma plc6-K - Amryt Pharma plc (0001783010) (Filer)
- PRAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 Dublin, Ireland, February 16, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, announced today that it has published a scheme circular (the "Scheme Circular") to its shareholders regarding the Amryt shareholder meetings to be held to consider and vote on the proposed acquisition of Amryt (the "Transaction") by Chiesi Farmaceutici S.p.A., an Italian società per azioni. As set forth in the Scheme Circula
- 13D/GSEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
- 13D/GSEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
- 13D/GSEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
- NEWSBenzinga's Top Ratings Upgrades, Downgrades For January 18, 2023Upgrades According to Citigroup, the prior rating for Pegasystems Inc (NASDAQ:PEGA) was changed from Neutral to Buy. In the third quarter, Pegasystems showed an EPS of $0.34, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.50 and a 52-week-low of $29.05. Pegasystems closed at $35.62 at the end of the last trading period. Mizuho upgraded the previous rating for Oatly Group AB (NASDAQ:OTLY) from Neutral to Buy. Oatly Group earned $0.18 in the third quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $7.98 and a 52-week-low of $1.28. At the end of the last trading period, Oatly Group closed at $2.69. Barclays
- NEWSHC Wainwright & Co. Downgrades Amryt Pharma to NeutralHC Wainwright & Co. analyst Douglas Tsao downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Neutral.
AMYT FAQ
7 questionsWhat does Amryt Pharma plc do?
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with...What is the latest news on AMYT?
Quantisnow has not tracked any new filings, ratings or press releases for AMYT in the last 30 days. The most recent wire item was published on April 24, 2023.Where does AMYT stock trade?
Amryt Pharma plc (AMYT) is listed on NASDAQ.What sector and industry is AMYT in?
Amryt Pharma plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AMYT?
Amryt Pharma plc has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $19.00 price target on 2022-09-06. Recent price targets range from $10.00 to $45.00.What companies are similar to AMYT?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare AMYT side-by-side with any of them on Quantisnow.How can I track AMYT on Quantisnow?
Quantisnow aggregates Amryt Pharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMYT to receive live email and push alerts on every new disclosure.